218 related articles for article (PubMed ID: 21107549)
1. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.
Vrabec M; Van Cauter S; Himmelreich U; Van Gool SW; Sunaert S; De Vleeschouwer S; Suput D; Demaerel P
Neuroradiology; 2011 Oct; 53(10):721-31. PubMed ID: 21107549
[TBL] [Abstract][Full Text] [Related]
2. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
3. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
4. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy.
Bobek-Billewicz B; Stasik-Pres G; Majchrzak H; Zarudzki L
Folia Neuropathol; 2010; 48(2):81-92. PubMed ID: 20602289
[TBL] [Abstract][Full Text] [Related]
5. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma.
Stecco A; Pisani C; Quarta R; Brambilla M; Masini L; Beldì D; Zizzari S; Fossaceca R; Krengli M; Carriero A
J Neurooncol; 2011 Apr; 102(2):261-71. PubMed ID: 20658351
[TBL] [Abstract][Full Text] [Related]
6. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
[TBL] [Abstract][Full Text] [Related]
8. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
10. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
[TBL] [Abstract][Full Text] [Related]
12. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
13. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
[TBL] [Abstract][Full Text] [Related]
14. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
Bauer AH; Erly W; Moser FG; Maya M; Nael K
Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
[TBL] [Abstract][Full Text] [Related]
16. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
[TBL] [Abstract][Full Text] [Related]
17. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
19. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]